Voyager Therapeutics (VYGR) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$31.3 million.
- Voyager Therapeutics' Free Cash Flow fell 1073.12% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.9 million, marking a year-over-year decrease of 31468.84%. This contributed to the annual value of -$18.8 million for FY2024, which is 12522.13% down from last year.
- Latest data reveals that Voyager Therapeutics reported Free Cash Flow of -$31.3 million as of Q3 2025, which was down 1073.12% from -$34.4 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Free Cash Flow registered a high of $123.1 million during Q1 2023, and its lowest value of -$38.6 million during Q1 2025.
- Over the past 5 years, Voyager Therapeutics' median Free Cash Flow value was -$21.4 million (recorded in 2021), while the average stood at -$6.2 million.
- As far as peak fluctuations go, Voyager Therapeutics' Free Cash Flow soared by 25983.39% in 2023, and later plummeted by 149154.03% in 2024.
- Quarter analysis of 5 years shows Voyager Therapeutics' Free Cash Flow stood at $10.8 million in 2021, then tumbled by 221.47% to -$13.2 million in 2022, then plummeted by 86.04% to -$24.5 million in 2023, then skyrocketed by 40.1% to -$14.7 million in 2024, then plummeted by 112.85% to -$31.3 million in 2025.
- Its last three reported values are -$31.3 million in Q3 2025, -$34.4 million for Q2 2025, and -$38.6 million during Q1 2025.